类似葡萄糖类-1受体激动剂-经验丰富的2型糖尿病成年人切换到现实世界设置中的每周一次的Semaglutide:SURE程序后期分析
Gottfried Rudofsky1, Markus Menzen2, Louis Potier3
1Praxis für Endokrinologie, Diabetes und Adipositas, Olten, Solothurn, Switzerland. Gottfried.rudofsky@hin.ch.
Advances in therapy
|December 5, 2024
概括
从其他GLP-1RAs转换为每周一次的Semaglutide (OW),在2型糖尿病患者中改善了血糖控制和减轻体重. 这种现实世界的证据证实了对于那些对先前治疗没有充分反应的人来说,额外的好处.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药物治疗 药物治疗
背景情况:
- 2型糖尿病的管理通常涉及逐步加强治疗.
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是一种关键的抗糖尿病药物.
- 在现实环境中评估治疗转换对于优化患者护理至关重要.
研究的目的:
- 为了评估从其他GLP-1受体激动剂 (GLP-1RAs) 转换为每周一次 (OW) 血红的有效性,在患有2型糖尿病的成年人中.
- 分析之前曾接触GLP-1RA的患者血糖控制和体重的变化.
- 在现实世界的临床实践环境中识别OW赛马格卢提德的益处和安全性.
主要方法:
- 对SEMAGLUTIDE现实世界证据 (SURE) 项目的特设后期分析,包括九项观察性研究.
- 包括651名从另一种GLP-1RA转换为OW血红的患者.
- 使用随机系数调整混合模型进行统计分析,用于重复测量和描述性统计.
主要成果:
- 在30周内,HbA1c显著减少0.67%点,体重减少3.69公斤.
- 在27.6%的患者中,达到≥5%的体重减轻.
- 在33.3%的基线HbA1c≥7%的患者中,达到血糖目标 (HbA1c<7%).
结论:
- 切换到OW血糖和体重管理为2型糖尿病患者提供额外的葡萄糖和体重管理好处,其他GLP-1RAs控制不充分.
- 每周服用一次的剂量方案提高了患者的便利性.
- 没有发现新的安全问题,支持其在临床实践中的使用.
相关概念视频
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
01:16Insulin: Dosing Regimen and Adverse Effects
145
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145
01:06Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
01:15Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152